Nucleic acid and corresponding protein entitled 161P2F10B...

Details Nucleic acid and corresponding protein entitled 161P2F10B... Nucleic acid and corresponding protein entitled 161P2F10B...

2011-07-12

2011-07-12

Goddard, Laura B (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100

Reexamination Certificate

active

07977062

ABSTRACT:
A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

REFERENCES:
patent: 5001225 (1991-03-01), Taylor
patent: 6323321 (2001-11-01), Buhring
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 7067130 (2006-06-01), Challita-Eid et al.
patent: 7226594 (2007-06-01), Jakobovits et al.
patent: 7405290 (2008-07-01), Challita-Eid et al.
patent: 7811565 (2010-10-01), Jakobovits et al.
patent: 2002/0137139 (2002-09-01), Byatt et al.
patent: 2003/0165505 (2003-09-01), Challita-Eid et al.
patent: 2003/0191073 (2003-10-01), Challita-Eid et al.
patent: 2003/0206905 (2003-11-01), Challita-Eid et al.
patent: 2005/0055733 (2005-03-01), Sun et al.
patent: 2005/0265921 (2005-12-01), Challita-Eid et al.
patent: 2005/0265924 (2005-12-01), Challita-Eid et al.
patent: 2006/0002993 (2006-01-01), Challita-Eid et al.
patent: 2006/0275211 (2006-12-01), Challita-Eid et al.
patent: 2007/0004913 (2007-01-01), Challita-Eid et al.
patent: 2007/0031335 (2007-02-01), Jakobovits et al.
patent: WO-99/60164 (1999-11-01), None
patent: WO-00/21990 (2000-04-01), None
patent: WO-01/57272 (2001-08-01), None
patent: WO-01/57273 (2001-08-01), None
patent: WO-01/57274 (2001-08-01), None
patent: WO-01/57275 (2001-08-01), None
patent: WO-01/57276 (2001-08-01), None
patent: WO-01/57277 (2001-08-01), None
patent: WO-01/57278 (2001-08-01), None
patent: WO-01/60860 (2001-08-01), None
patent: WO-01/75067 (2001-10-01), None
patent: WO-01/86003 (2001-11-01), None
patent: WO-02/079411 (2002-10-01), None
patent: WO-03/004514 (2003-01-01), None
patent: WO-03/016475 (2003-02-01), None
patent: WO-03/040340 (2003-05-01), None
patent: WO-03/048779 (2003-06-01), None
Buhring et al I (Blood, 1999, 94:2343-2356).
Buhring et al II (Blood, May 2001, 97:3303-3305).
Alcocer et al (J Agric Food Chem, 2000, 48:4053-4059).
Amalfitano et al., Current Gene Therapy (2002) 2:111-133.
Andoh et al., “Genomic structure and promoter analysis of the ecto-phosphodiesterase I gene (PDNP3) expressed in glial cells,” Biochimica et Biophysica Acta (1999) 1446(3):213-224.
Boehringer Mannheim Biochemicals, 1994 Catalog, p. 93.
Bollen et al., “Nucleotide pyrophosphatases/phosphodiesterases on the move,” Critical Reviews in Biochemistry and Molecular Biology (2000) 35(6):393-432.
Buehring et al., Tissue Antigens (2000) 55(Suppl. 01):68.
Buhring et al., Blood 94(7):2343-2356 (1999).
Buhring et al., Blood 97(10):3303-3305 (2001).
Burgess et al., Journal of Cell Biology 111:2129-2138 (1990).
Colbern et al., J. lnorg. Biochem. (1999) 77:117-120.
Coleman, Research in Immunology 145:33-36 (1994).
Database EMBL [Online] Accession No. AK024899 (Sep. 29, 2000).
Database Geneseq [Online] Accession No. ADE56103 (Jan. 29, 2005).
Deissler et al., Journal of Biological Chemistry (1995) 270(17):9849-9855.
Dennis, Nature (2006) 442:739-741.
Dillman, Annals of Internal Medicine (1989) 111:592-603.
Goding et al., Biochimica et Biophysica Acta (2003) 1638(1):1-19.
Houdebine, Journal of Biotechnology (1994) 34:269-287.
Houghton and Scheinberg, Seminars in Oncology (1986) 13:165-179.
International Search Report for PCT/US02/36002, mailed on Jan. 5, 2005, 5 pages.
International Search Report and Written Opinion for PCT/US06/12314, mailed Jan. 11, 2008, 7 pages.
Jain, Scientific American (1994) 271:58-65.
Jiang et al., J. Biol. Chem. (2005) 280(6):4656-4662.
Jin-Hua et al., Genomics 45(2):412-415 (1997).
Lazar et al., Molecular and Cellular Biology 8(3):1247-1252 (1988).
Lederman et al., Molecular Immunology 28:1171-1181 (1991).
Lewin, ed., Genes VI, Chapter 29, pp. 847-848 (1997).
Li et al., Proc Natl Acad Sci USA 77:3211-3214 (1980).
Maurice et al., “Biosynthesis and intracellular transport of a bile canalicular plasma membrane protein: studies in vivo and in the perfused rat liver,” Hepatology (1994) 19(3):648-655.
Maurice et al., “Characterization of rat hepatocyte plasma membrane domains by monoclonal antibodies,” European Journal of Cell Biology (1985) 39(1):122-129.
McCormick, Nature Reviews (2001) 1:130-141.
Meibohm, ed., Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VHC, 2006, Chapter 3, pp. 45-91.
NCBI Accession No. NP—004439, Version: NP—004439.1, GI:4758298, PRI date: Oct. 14, 1999, pp. 1-4.
Pandha et al., Current Opinion in Investigational Drugs (2000) 1:122-134.
Paul (Ed.), Fundamental Immunology, 3rd ed., p. 242 (1993).
PN IM3575, 100 tests, 20 μL/test, IOTest Conjugated Antibodies, Immunotech, A Coulter Company, Vers. 01, Apr. 4, 2001, retrieved from Internet.
Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlag, Berlin (1976).
Rolland, Advanced Drug Delivery Reviews (2005) 57:669-673.
Schwartz et al., Proc Natl Acad Sci USA 84:6408-6411 (1987).
Scott et al., “Biochemical and molecular identification of distinct forms of alkaline phosphodiesterase I expressed on the apical and basolateral plasma membrane surfaces of rat hepatocytes,” Hepatology (1997) 25(4):995-1002.
Srivastava, Nature Immunology (2000) 1(5):363-366.
Stancoviski et al., PNAS USA (1991) 88:8691-8695.
Supplementary Partial European Search Report for EP 02 79 7088.8, mailed on Oct. 25, 2006, 7 pages.
Supplementary European Search Report for EP 02 79 7088, mailed on Feb. 5, 2007, 8 pages.
Supplementary European Search Report for EP 06749164.7, mailed Aug. 20, 2009, 12 pages.
Verma et al., Nature (1997) 389:239-242.
Weiner, Seminars in Oncology (1999) 26(Suppl. 12):41-50.
White et al., Ann Rev Med (2001) 52:125-145.
Yano et al., Cancer Letters (2004) 207(2):139-147.
Yano et al., International Journal of Molecular Medicine (2003) 12(5):763-766.
Restriction Requirement for U.S. Appl. No. 10/005,480, mailed on May 24, 2004.
Response to Restriction Requirement and Amendment Under 37 CFR § 1.111 for U.S. Appl. No. 10/005,480, filed Jun. 18, 2004.
Non-Final Office Action for U.S. Appl. No. 10/005,480, mailed on Aug. 17, 2004.
Restriction Requirement for U.S. Appl. No. 10/062,109, mailed on Jul. 9, 2004.
Response to Restriction Requirement for U.S. Appl. No. 10/062,109, filed Jul. 15, 2004.
Non-Final Office Action for U.S. Appl. No. 10/062,109, mailed on Aug. 25, 2004.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/062,109, filed Sep. 17, 2004.
Final Office Action for U.S. Appl. No. 10/062,109, mailed on Nov. 12, 2004.
Amendment After Final Action (37 CFR § 1.116) for U.S. Appl. No. 10/062,109, filed Dec. 1, 2004.
Notice of Allowance for U.S. Appl. No. 10/062,109, mailed on May 4, 2005.
Non-Final Office Action for U.S. Appl. No. 10/860,769, mailed on Dec. 5, 2006.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/860,769, filed Mar. 5, 2007.
Non-Final Office Action for U.S. Appl. No. 10/859,643, mailed on Nov. 13, 2006.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/859,643, filed Mar. 5, 2007.
Non-Final Office Action for U.S. Appl. No. 11/097,912, mailed on Nov. 6, 2006.
Non-Final Office Action for U.S. Appl. No. 11/097,864, mailed on Oct. 19, 2006.
Restriction Requirement for U.S. Appl. No. 10/291,241, mailed on Sep. 21, 2005.
Response to Restriction Requirement, filed Nov. 18, 2005.
Non-Final Office Action for U.S. Appl. No. 10/291,241, mailed on Dec. 29, 2005.
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 10/291,241, filed Jan. 10, 2006.
Final Office Action for U.S. Appl. No. 10/291,241, mailed on Apr. 5, 2006.
Amendment After Final Action (37 CFR § 1.116) for U.S. Appl. No. 10/291,241, file

Affiliated with

Also associated with

Rating

Nucleic acid and corresponding protein entitled 161P2F10B... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acid and corresponding protein entitled 161P2F10B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid and corresponding protein entitled 161P2F10B... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2651950